The Pan Canadian Expert Review Committee has recommended the funding of pomalidomide (Pomalyst) for patients with relapsed and/or refractory multiple myeloma who have previously failed two treatments, including both bortezomib and lenalidomide, and who have demonstrated disease progressed on last treatment, conditional on its cost-effectiveness being improved to an acceptable level. Pomalidomide should also be considered an option when the use of bortezomib is contra-indicated, where it cannot be administered logistically, or when patients are not able to tolerate it, but in all cases, patients should have failed the use of lenalidomide.

For more details, go to: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-pomalyst-mm-fn-rec.pdf